Is a complete CRVS research report available?

No complete published report is available for Corvus Pharmaceuticals, Inc. (CRVS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · USD

$13.2

+0.15 (+1.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CRVS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	1.1B
Net income (ttm)	-44.2M
EPS (ttm)	-$0.55
Shares out	84.1M
Volume	963,009
Beta	0.82
Price target	$33.1	+151.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -44.2M
EPS (ttm): -$0.55
Market cap: 1.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CRVS indicators

Market & fundamental data

Available fields

187

Groups with data

Currency

USD

Showing 187 of 187 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001626971
Company name	Corvus Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	221015100
Employees	37
Employees Change	6%
Employees Change Percent	19.35
Enterprise value	$873.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2016-03-23
Isin	US2210151005
Last refreshed	2026-07-31
Market cap	$1.1B
Market cap category	Small-Cap
Price	$13.19
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	CRVS
Website	https://www.corvuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.98%
FCF yield	-3.17%
P/B ratio	4.61x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-44.2M
Net Income Growth Years	1%
Profit Per Employee	$-1.2M
ROA	-19.16
Roa5y	-28.24
ROCE	-19.88
ROE	-30.46
Roe5y	-73.89
ROIC	-20.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.03%
Cagr1y	192.03%
Cagr3y	79.23%
Cagr5y	43.61%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$253.2M
Cash	$236.7M
Current Assets	$239.9M
Current Liabilities	$12.1M
Debt	$834,000
Debt Equity	$0
Equity	$240.7M
Liabilities	$12.5M
Long Term Assets	$13.2M
Long Term Liabilities	$406,000
Net Cash	$235.9M
Net Cash By Market Cap	$21.27
Net Cash Growth	447.81%
Net Debt Equity	$-0.98
Tangible Book Value	$240.7M
Tangible Book Value Per Share	$2.86
WACC	8.74

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	19.81
Net Working Capital	$-8.5M
Quick ratio	19.65
Working Capital	$227.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-24.98%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	0.3%
1Y total return	191.81%
200-day SMA	12.93
3Y total return	475.98%
50-day SMA	13.22
50-day SMA vs 200-day SMA	50over200
5Y total return	510.65%
All Time High	26.95
All Time High Change	-51.06%
All Time High Date	2026-01-23
All Time Low	0.61
All Time Low Change	2,072.98%
All Time Low Date	2023-03-28
ATR	0.76
Beta	0.82
Beta1y	0.83
Beta2y	1.07
Ch YTD	71.3
High	13.33
High52	26.95
High52 Date	2026-01-23
High52ch	-51.06%
Low	12.92
Low52	3.96
Low52 Date	2025-08-01
Low52ch	233.08%
Ma50ch	-0.26%
Premarket Change Percent	0.84
Premarket Price	$13.15
Premarket Volume	3,439
Price vs 200-day SMA	2%
RSI	43.42
RSI Monthly	58.09
RSI Weekly	49.7
Sharpe ratio	1.09x
Sortino ratio	4.37
Total Return	-24.98%
Tr YTD	71.3
Tr1m	-8.91%
Tr1w	-3.58%
Tr3m	-8.53%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	4
Analyst Price Target Top	$32.75
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.17
Operating Income	$-47.9M
Price target	$33.14
Price Target Change	$151
Price Target Change Top	$148

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	72,758,299%
Float Percent	86.52%
Shares Insiders	3.54%
Shares Institutions	75.62%
Shares Out	84,090,424
Shares Qo Q	8.48%
Shares Yo Y	24.98%
Short Float	24.82%
Short Ratio	12.38
Short Shares	21.48

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-41.9M
Adjusted OCF	-41,637,000
Average Volume	1,077,744.9x
Bv Per Share	2.86
CAPEX	$-229,000
Ch10y	0.3
Ch1m	-8.91
Ch1w	-3.58
Ch1y	191.8
Ch3m	-8.53
Ch3y	476
Ch5y	510.6
Ch6m	-37.01
Change	1.15%
Change From Open	0.3
Close	13.04
Days Gap	0.84
Depreciation Amortization	112,000
Dollar Volume	12,702,088.7
Earnings Date	2026-08-06
Earnings Time	amc
EBIT	$-47.9M
EBITDA	$-47.8M
EPS	$-0.55
F Score	2
FCF	$-35.1M
FCF EV Yield	-4.02x
FCF Per Share	$-0.42
Financing CF	226,896,000
Fiscal Year End	December
Founded	2,014
Investing CF	-156,885,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-12
Ma150	14.56
Ma150ch	-9.38%
Ma20	14.48
Ma20ch	-8.88%
Net CF	35,103,000
Next Earnings Date	2026-08-06
Open	13.15
Optionable	Yes
Position In Range	65.85
Post Close	13.19
Postmarket Change Percent	1.97
Postmarket Price	$13.45
Ppne	1,033,000
Pre Close	13.04
Price Date	2026-07-30
Ptbv Ratio	4.61
Relative Volume	0.89x
Share Based Comp	6,729,000
Tr6m	-37.01%
Us State	California
Volume	963,009

Corvus Pharmaceuticals, Inc. (CRVS)

Coverage state: Market snapshot only — no published research

Generate the first CRVS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CRVS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CRVS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CRVS

Frequently asked questions